

November 16, 2022

Notice Concerning the Establishment of Michiteku Co., Ltd.

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “ONO”) today announced that it established michiteku Co., Ltd. (michiteku) as a wholly-owned subsidiary on November 16, which serves to process and provide information as a main business in the healthcare field.

1. Purpose for establishment:

ONO focused on the physical, mental, and psychological problems of cancer patients that cannot be solved by drugs in the oncology field. In order to resolve the burden of cancer patients and social issues, ONO determined that it would be important to engage in information processing and provision services in the healthcare field. In order to provide such services to as many cancer patients and their families as possible while making the most of our experience and know-how accumulated in research and development (R&D) in the oncology and immunology fields, we have established a subsidiary to promote new businesses in an organization independent of the R&D and marketing divisions of pharmaceutical products.

Michiteku will be committed to resolving social issues surrounding cancer patients by developing information processing and provision services in the healthcare field.

2. Outline of michiteku Co., Ltd.

Name	michiteku Co., Ltd.
Location	9-11, Nihonbashi-Honcho 4-chome, Chuo-ku, Tokyo
Representative	Hitoshi Mito, President
Establishment	November 16, 2022
Capital	JPY 10 million
Staff	5 persons
Business	Information processing and provision services in the healthcare field
Relationship	A wholly-owned subsidiary of ONO

3. Future outlook

An impact of this matter on the Company’s business results for the current fiscal year would be marginal. Should there be any events to be disclosed in the future, we will announce them in a timely manner.

Contact:

Ono Pharmaceutical Co., Ltd.

Corporate Communications

public_relations@ono-pharma.co.jp